Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate).

Literature DB >> 1605902

Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate).

K S Eyres¹, P Marshall, E McCloskey, D L Douglas, J A Kanis.

Abstract

The recommended regimen of etidronic acid (disodium etidronate) for the treatment of Paget's disease of bone is 5mg/kg/day for a period of less than six months. There have, however, been reports of impaired mineralisation of bone and concern that the risk of fracture is increased with this dosage. We report a patient with Paget's disease in whom fractures occurred through pagetic and non-pagetic bone which appeared to be causally related to treatment with lose doses of etidronic acid. The osteomalacia resolved when etidronic acid was discontinued.

Entities: Chemical Disease Species

Mesh：

Substances：
Etidronic Acid

Year: 1992 PMID： 1605902 DOI： 10.2165/00002018-199207020-00008

Source DB: PubMed Journal: Drug Saf ISSN： 0114-5916 Impact factor: 5.606

15 in total

1. Calcitonin or diphosphonates for osteolytic Paget's disease?

Authors: C Nagant de Deuxchaisnes; C Rombouts-Lindemans; J P Huaux; J P Devogelaer; J Malghem; B Maldague
Journal: Lancet Date: 1980-02-16 Impact factor: 79.321

2. Etidronate and the risk of fractures.

Authors: C Nagant de Deuxchaisnes; J P Dufour; J P Devogelaer; J P Huaux; W Esselinckx
Journal: Lancet Date: 1985-09-14 Impact factor: 79.321

3. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors: W B Frijlink; O L Bijvoet; J te Velde; G Heynen
Journal: Lancet Date: 1979-04-14 Impact factor: 79.321

4. Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment.

Authors: R Smith; R G Russell; M C Bishop; C G Woods; M Bishop
Journal: Q J Med Date: 1973-04

5. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).

Authors: R D Altman; C C Johnston; M R Khairi; H Wellman; A N Serafini; R R Sankey
Journal: N Engl J Med Date: 1973-12-27 Impact factor: 91.245

6. Treatment of Paget disease of bone (osteitis deformans). Results of a one-year study with sodium etidronate.

Authors: M R Khairi; C C Johnston; R D Altman; H N Wellman; A N Serafini; R R Sankey
Journal: JAMA Date: 1974-10-28 Impact factor: 56.272

7. Letter: Disodium ethane-1-hydroxy-1, 1-diphosphonate(E.H.D.P.) in Paget's disease.

Authors: G Fromm; F Schajowicz; C A Mautalen
Journal: Lancet Date: 1975-10-04 Impact factor: 79.321

8. Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone.

Authors: C Alexandre; P J Meunier; C Edouard; R A Khairi; C C Johnston
Journal: Metab Bone Dis Relat Res Date: 1981

Review 2. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors: C J Dunn; A Fitton; E M Sorkin
Journal: Drugs Aging Date: 1994-12 Impact factor: 3.923

Review 3. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.

Authors: David Y Graham
Journal: Dig Dis Sci Date: 2002-08 Impact factor: 3.199

Review 4. Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.

Authors: Jean-Yves Reginster; Olivier Malaise; Audrey Neuprez; Victor-Emmanuel Jouret; Pierre Close
Journal: Drugs Aging Date: 2007 Impact factor: 3.923

4 in total